Spark Time!

Simon Goldman manages the UCL Tech Fund’s life sciences team through Albion VC – he’s especially interested in cell and gene therapies, and shares with us his perspectives on translating science out of academia and into the clinic, as well as what selling means in the US versus the UK. Finally, another Australian joins the podcast!

Roy Baynes M.D., Ph.D, has been instrumental in developing some of the most impactful drugs, including Keytruda. Listen in as he shares his learnings from decades of innovation in cancer treatment across pharma, biopharma and biotech.

Chris Hoyt is a biotech exec focused on advancing cures for neurodegenerative disease, but he comes from a tech background. Listen in as he speaks candidly about what the field has been through, and how he relishes the opportunity to progress treatments for patients who need them.

Dillan Dinardo is a seasoned healthcare investor turned psychedelic medicine leader. Join us as he discusses how psychedelic medicine is the next frontier of mental health care, and how the field is driving scientific innovation to transformative change.

Explore the entrepreneurial path of John Lewis with us – from Canadian income tax consultant to biotech exec, John has carried a passion for building teams and putting innovation to work to solve some big problems in drug delivery.

David Lucchino, former Chairman of Mass Bio and CEO of Frequency, has seen every situation from the helm. Join us as we discuss his strategies for communication, and how teamwork and relationship building fuels his successes.

Josh Schimmer is the preeminent equity analyst in the biotech industry; he's seen the good, the bad, and the ugly. Join us as we dive deep into his experiences reviewing corporate decks, the consequence of a deck falling short and the missed opportunity for a relationship.

Colin Sanford is a biotech PR expert, join us as he discusses the importance of on-boarding a comms team early and growing that relationship to ensure  your well-executed communication strategy can drive scientific innovation to transformative change.

Melissa Moore is a pioneering scientist and an engaging storyteller.  Join us as she discusses how compelling storytelling in science communication can drive scientific innovation to transformative change.

Join us as we discuss with Garrett Vygantas the essential elements of messaging from a biotech VC investor’s perspective.